Results 111 to 120 of about 10,049 (144)

Postmarket Safety Actions for Novel Oncology Drugs Granted FDA's Accelerated Approval.

JAMA Netw Open
Mooghali M, Wallach JD, Mitchell AP, Ross JS, Ramachandran R.   +4 more
europepmc   +1 more source

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System. [PDF]

JAAD Int
Alomary SA, Baker NJ, Ogunleye T, Taylor SC.   +3 more
europepmc   +1 more source

GLP-1 receptor agonists and functional gastrointestinal obstruction: mechanistic rationale, emerging evidence, and clinical implications. [PDF]

Ann Med Surg (Lond)
Riaz L, Ajmal A, Siddiquei H, Memon U, Jaber Amin JH.   +4 more
europepmc   +1 more source

Mid- to Long-term Outcomes Following Primary Augmentation With B-Lite Lightweight Breast Implants: A Prospective Multicenter Postmarketing Clinical Follow-up Study. [PDF]

Aesthet Surg J
Reichenberger M, Hedén P, Germann G.
europepmc   +1 more source

Expedited research and approval of medicines for drug-resistant bacterial infections in children. [PDF]

Bull World Health Organ
Williams PC, Noel GJ, Nambiar S, O'Brien S, Paterson DL, Bielicki JA, Sharland M, Bradley JS.   +7 more
europepmc   +1 more source

Adverse events associated with use of immunoglobulin in pediatric patients reported to the US Food and Drug Administration Adverse Event Reporting System, 2001-2023. [PDF]

Pediatr Allergy Immunol
Wei S, Kim Y, Rubin MN, Ayyala SS, Welsh K.   +4 more
europepmc   +1 more source

Policy Without Penalty: A Review of Pediatric Research Equity Act Noncompliance Letters. [PDF]

Pediatrics
Green DJ, Pagano A, Goldman J, Deshmukh AD.   +3 more
europepmc   +1 more source

Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence. [PDF]

Front Pharmacol
Dong Y, Zhi Y, Li X, Ma M, Ye M, Huang S, Tang J, Zhong W, Lei X, Mao Y.   +9 more
europepmc   +1 more source

Japanese evidence on Janus kinase inhibitors for rheumatoid arthritis: a narrative review of risk-optimized use. [PDF]

Front Pharmacol
Matsumoto H, Yoshida S, Tahara M, Nibu H, Yamamoto S, Sakamoto T, Ogawa S, Saito K, Sumichika Y, Suzuki E, Asano T, Sato S, Shimojima Y.   +12 more
europepmc   +1 more source